Both IDH1-mutant and wild-type murine gliomas reached the tumor morbidity end stage with a median survival of 40 days post-injection (Figure 1A), suggesting the IDH1 mutation did not facilitate or inhibit gliomagenesis in this co-delivery model. This evidence concerns the gene IDH1 and central nervous system cancer.